Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Operating Leases (2019 - 2025)

CorMedix has reported Operating Leases over the past 7 years, most recently at $2.3 million for Q4 2025.

  • Quarterly results put Operating Leases at $2.3 million for Q4 2025, up 545.56% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (up 545.56% YoY), and the annual figure for FY2025 was $2.3 million, up 545.56%.
  • Operating Leases reached $2.3 million in Q4 2025 per CRMD's latest filing, down from $2.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $2.4 million in Q3 2025 and bottomed at $304092.0 in Q1 2025.
  • Median Operating Leases over the past 5 years was $685289.5 (2022), compared with a mean of $803047.6.
  • The largest annual shift saw Operating Leases surged 47205.04% in 2021 before it crashed 44.1% in 2024.
  • Over 5 years, Operating Leases stood at $802433.0 in 2021, then decreased by 16.8% to $667632.0 in 2022, then dropped by 22.56% to $517000.0 in 2023, then plummeted by 32.5% to $349000.0 in 2024, then soared by 545.56% to $2.3 million in 2025.
  • Business Quant data shows Operating Leases for CRMD at $2.3 million in Q4 2025, $2.4 million in Q3 2025, and $435000.0 in Q2 2025.